Evidence map›Paper›PMID 41808730›Full record

ArticleBlood neoplasia2026

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Christoph Weigel, Haley L Klimaszewski, Fode Tounkara, Selamawit Addissie, Sarah Schlotter, Betsy Pray, James P Dugan, Bradley M Haverkos, Lynda Villagomez, Mark Lustberg and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Christoph WeigelDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Haley L KlimaszewskiCollege of Medicine, The Ohio State University, Columbus, OH.
Fode TounkaraCenter for Biostatistics, The Ohio State University, Columbus, OH.
Selamawit AddissieDepartment of Internal Medicine, Johns Hopkins University, Baltimore, MD.
Sarah SchlotterCollege of Medicine, The Ohio State University, Columbus, OH.
Betsy PrayDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
James P DuganMalignant Hematology and Cellular Therapy Department, Novant Health Cancer Institute - Forsyth Medical Center, Winston-Salem, NC.
Bradley M HaverkosDivision of Hematology, University of Colorado School of Medicine, Aurora, CO.
Lynda VillagomezDivision of Hematology and Oncology, Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital, Columbus, OH.
Mark LustbergDivision of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Pierluigi PorcuDivision of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Timothy VoorheesDepartment of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
Richard F AmbinderDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Shannon C KenneyDepartment of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI.
Joyce FingerothDepartment of Medicine, Chan Medical School, University of Massachusetts, Worcester, MA.
Henri-Jacques DeleclusePathogenesis of Virus Associated Tumors, German Cancer Research Center, Heidelberg, Germany.
Michael A CaligiuriDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA.
Lapo AlinariDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Ginny BumgardnerComprehensive Transplant Center, Department of Surgery, The Ohio State University College of Medicine, Columbus, OH.
Christopher C OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Robert A BaiocchiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV)-associated primary central nervous system lymphoproliferative diseases (EBV+PCNSL) are aggressive conditions with poor prognoses. We previously reported durable responses in patients with PCNSL who were treated with the antivirals ganciclovir and azidothymidine, plus rituximab and dexamethasone (GARD). Responses were associated with the detection of the lytic viral protein kinases, BGLF4 and BXLF1. These antiviral activating kinases are associated with lytic EBV, however, the mechanism for expression in latently infected EBV+CNSL is unknown. Expanding on previous work, we provide long-term clinical outcome data (N = 24) and show that RNA expression analysis in CNSL tissue biopsies (n = 12) confirmed the expression of

Identifiers

PMID41808730
PMCPMC12969294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.